{
    "root": "2c3d221b-f0d3-4845-8bbc-9a4df2f0cc33",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Eslicarbazepine Acetate",
    "value": "20250507",
    "ingredients": [
        {
            "name": "ESLICARBAZEPINE ACETATE",
            "code": "BEA68ZVB2K"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED",
            "code": "2165RE0K14"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        }
    ],
    "indications": "Eslicarbazepine acetate tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older.",
    "contraindications": "Adult Patients: The recommended initial dosage of      eslicarbazepine acetate tablets is 400 mg once daily. For some patients,      treatment may be initiated at 800 mg once daily if the need for seizure      reduction outweighs an increased risk of adverse reactions. Increase the      dose in weekly increments of 400 mg to 600 mg once daily, based on      clinical response and tolerability, to a recommended maintenance dosage of      800 mg to 1,600 mg once daily.  ( 2.2 ) Pediatric Patients: The recommended dosage of eslicarbazepine      acetate tablets is based on body weight and is administered orally once      daily.  Increase the dose in weekly intervals based on clinical response      and tolerability, to the recommended maintenance dosage ( 2.2 ). Patients with Moderate or Severe Renal Impairment: Reduce      dosage by 50%. ( 2.4 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "Eslicarbazepine acetate tablets are contraindicated in patients with a hypersensitivity to eslicarbazepine acetate or oxcarbazepine [see Warnings and Precautions (5.2, 5.3, and 5.4)]."
}